About Fuda Cancer Hospital

Guangzhou Fuda Cancer Hospital

Under the administration of the Health Commission of Guangdong Province, Guangzhou Fuda Cancer Hospital is an international-oriented oncology-specialized hospital integrating medical care, teaching, scientific research, disease prevention and healthcare. Guided by high and new technologies, it features minimally invasive therapies, and is the first oncology-specialized hospital in Guangdong Province accredited by Joint Commission International (JCI). The hospital consists of the Tianhe Campus and Haizhu Campus, with a total floor area of over 30,000 m², 400 open beds and 45 VIP rooms.

In 2010, the former Ministry of Health designated FUDA Cancer Hospital as one of the first batch of National Key Clinical Cancer Speciality Centres (Oncology). In 2017, the Hospital was awarded the title of Civilized Unit of Guangdong Province. In 2018, the Hospital was officially accredited as a National Key Clinical Specialty (Oncology). In 2019, the Hospital was named a High-level Key Clinical Cancer Speciality Centre of Guangdong Province (Oncology). In 2021, the Hospital Party Committee was conferred the honorary title of Advanced Grassroots Party Organization of Guangdong Province. The Hospital has received multiple honors including National Trustworthy Private Hospital and Top-100 National Trustworthy Demonstration Hospital for the Public. It is a designated medical institution for nationwide inter-provincial on-the-spot medical insurance settlement, a designated unit for provincial-level and municipal-level public-funded medical care of Guangdong, as well as a designated hospital under Guangzhou Municipal Medical Insurance Scheme.

Upholding its hospital motto “Practising medicine with great virtue; advancing medical ethics in solidarity”, and adhering to the hospital-running guidelines “Prospering the hospital through science and technology, sustaining the hospital through integrity, operating the hospital with benevolence”, the hospital pursues a development path of high-end positioning, academic emphasis and international outreach. It has developed the distinctive 3C+P Model of comprehensive personalized care, consisting of Cryo-Irreversible Electroporation Ablation (CIA), Cancer Vascular Intervention (CVI), and Combined Immunotherapy for Cancer (CIC), plus Personalized (P) comprehensive therapy. Patients from more than 130 countries and regions worldwide have been attracted to come, 60 % of whom are from Southeast Asia, the Middle East, Europe and North America.

Guangzhou Fuda Cancer Hospital fosters an institutional culture of “Shouldering responsibilities and devoting to public welfare”, and has long been committed to social welfare initiatives. The hospital has donated funds and supplies for disaster-stricken areas such as the Wenchuan and Ya’an earthquakes, taken part in public-benefit programmes including “Caring-for-People Charity Campaign of Guangzhou”, and established the Fuda Benevolence Foundation. Cumulative donations of funds and materials have exceeded RMB 20 million over the years. The Hospital has provided free physical examinations for more than 10,000 nearby elderly persons living alone. Through community free clinics, health lectures, financial assistance for impoverished patients and other outreach activities, it delivers tangible benefits to the general public and earnestly fulfils its social responsibilities.
🎓
World-Class Team
Graduates from top universities worldwide
🔬
Advanced R&D
Self-developed
🤖
Innovation Focus
Multiple innovative technologies

Company Gallery

Industry Problems Addressed

locally unresectable tumors, systemic metastasis, need to reduce systemic toxicity or preserve organ function with less invasive options

Healthcare - Hospital (Oncology specialty)

locally unresectable tumors, systemic metastasis, need to reduce systemic toxicity or preserve organ function with less invasive options

Impact: Business impact: for hospital—drives development of minimally invasive, interventional and immunotherapies and attracts international patients; for patients—more organ‑sparing, lower‑toxicity and life‑prolonging options.
Segment: Oncology specialty care and international patient services

Service Definitions

Comprehensive oncology services (cryoablation, NanoKnife, interventional, chemo/radiotherapy, immunotherapy)

Comprehensive oncology services (cryoablation, NanoKnife, interventional, chemo/radiotherapy, immunotherapy)

Medical services: oncology specialty clinical care, minimally invasive interventional treatments, immuno‑/cell therapies, rehabilitation and supportive care

Duration: Service cycle: varies widely by disease and plan—from single‑session interventions to long‑term systemic therapy and follow‑up; durations range from days to months or longer and require case‑by‑case confirmation.
Mode: Delivery: primarily on‑site outpatient/inpatient treatment; initial remote consultations and assessments offered via online appointment and tele‑evaluation.

Service Capabilities

Capability

Service Capabilities

Core Expertise: Core expertise: clinical application of cryoablation, IRE (NanoKnife), vascular interventional oncology and combined immunotherapy
Experience: 20 Years
Languages: English, Thai, Indonesian, Malay, Russian, Kazakh, Mongolian, Chinese, Cantonese

Service Solutions

3C+P Personalized Comprehensive Oncology Solution (Cryo-NanoKnife, Vascular Intervention,  Combined Immunotherapy + Personalization)

3C+P Personalized Comprehensive Oncology Solution (Cryo-NanoKnife, Vascular Intervention, Combined Immunotherapy + Personalization)

Overview: Overview: core of cryoablation, Nanoknife, vascular interventional oncology and combined immunotherapy, integrated with molecular testing and MDT for personalized plans
Features: Core features: multidisciplinary individualized decisions, combined minimally invasive ablation technology, international patient care and research support

Service Methodologies

MDT-led personalized 3C+P treatment methodology

MDT-led personalized 3C+P treatment methodology

Framework: MDT assessment → molecular/imaging diagnostics → personalized combined treatments (cryo/nanoknife/intervention/immuno/chemo-radio) → rehab & follow-up

Service Processes

Process Name Process Overview Key Steps Timeline Deliverables
Patient pathway: Consultation → MDT → Treatment → Follow-up Overview: online/phone appointment → outpatient assessment → imaging/molecular tests → MDT plan → treatment → rehab & follow-up - - -

Service Cases

Case Study

Client Industry: Individual patient (medical/international patient case)

Case Study

Client Industry: Case patient background: vehicle mechanic from Guangxi

Case Study

Client Industry: Patient is a student (case individual), not an industry client

Case Study

Client Industry: Patient (healthcare recipient)

Case Study

Client Industry: Patient family from the catering industry (case detail)

Service Performance

📊
Metric names: JCI accreditation, National Clinical Key Specialty designation, number of beds
50%
Definition: JCI denotes compliance with international patient safety & quality standards; bed count reflects capacity
Measurement period: depends on the metric (not specified on site)
Benchmark: Benchmark: peer JCI-accredited and national clinical key specialty oncology hospitals

Company & Product Videos

Company Introduction & Factory Tour

⏱ Duration: 3:45 | 👁 Views: 15,230

Product Demonstration - Kestrel K-1

⏱ Duration: 5:12 | 👁 Views: 28,450

Technology Innovation Showcase

⏱ Duration: 4:30 | 👁 Views: 12,890

Customer Testimonials & Success Stories

⏱ Duration: 6:20 | 👁 Views: 9,650

Ready to Transform Your Life?

Contact us immediately to learn how our products meet your needs.